Jaguar Health (JAGX) Convertible Debt (2017 - 2018)
Jaguar Health's (JAGX) quarterly Convertible Debt came in at $10.7 million in Q3 2018, down 4.48% year-on-year from $11.2 million in Q3 2017, and down 2.93% on a QoQ basis from $11.0 million in Q4 2017.
Jaguar Health (JAGX) Convertible Debt (2017 - 2018) Analysis & Trends
Jaguar Health (JAGX) has 2 years of Convertible Debt data on file, last reported at $10.7 million in Q3 2018.
- On a quarterly basis, Convertible Debt fell 4.48% year-over-year to $10.7 million in Q3 2018; TTM through Sep 2018 was $10.7 million, a 4.48% decrease from a year earlier, with the FY2017 full-year figure at $11.0 million, changed N/A from the prior year.
- Convertible Debt for Q3 2018 stood at $10.7 million, down from $11.0 million in the prior quarter.
- Over the last five years, Convertible Debt for JAGX reached as high as $11.2 million in Q3 2017 and fell as low as $10.7 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - |
| 10 | Jaguar Health | 497,735.41 | -9.57 Mn | 19.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 10.66 Mn |
| Dec 31, 2017 | 10.98 Mn |
| Sep 30, 2017 | 11.16 Mn |